Bringing a Leukemic Stem Cell Gene Signature into Clinics: Are We There Yet?
Guillaume Richard-Carpentier1, Guy Sauvageau2
1The Leucegene Project at the Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC H3C 3J7, Canada; Banque de Cellules Leucémiques du Quebec, Maisonneuve-Rosemont Hospital, Montréal, QC H1T 2M4, Canada.
Abstract:
Prognostic markers that capture leukemia stem cell (LSC) activity can be useful for the risk stratification of acute myeloid leukemia (AML) patients. In a recent issue of Nature, Ng et al. (2016) develop a prognostic score based on a 17-gene expression signature of LSCs to predict outcome in AML patients.
More Related Videos
09:34A Combinatorial Single-cell Approach to Characterize the Molecular and Immunophenotypic Heterogeneity of Human Stem and Progenitor Populations
Published on: October 25, 2018
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
Related Concept Videos
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
01:21Lineage Commitment